Long-term vaccinations with human b-amyloid peptide 1-42 (Ab1-42) have recently been shown to prevent or markedly reduce Ab deposition in the PDAPP transgenic model of Alzheimer's disease (AD). Using a similar protocol to vaccinate 7.5-month-old APP (Tg2576) and APP1PS1 transgenic mice over an 8-month period, we previously reported modest reductions in brain Ab deposition at 16 months. In these same mice, Ab vaccinations had no deleterious behavioral effects and, in fact, benefited the mice by providing partial protection from age-related deficits in spatial working memory in the radial arm water maze task (RAWM) at 15.5 months. By contrast, control-vaccinated transgenic mice exhibited impaired performance throughout the entire RAWM test period at 15.5 months. The present study expands on our initial report by presenting additional behavioral results following long-term Ab vaccination, as well as correlational analyses between cognitive performance and Ab deposition in vaccinated animals. We report that 8 months of Ab vaccinations did not reverse an early-onset balance beam impairment in transgenic mice. Additionally, in Y-maze testing at 16 months, all mice showed comparable spontaneous alternation irrespective of genotype or vaccination status. Strong correlations were nonetheless present between RAWM performance and extent of "compact" Ab deposition in both the hippocampus and the frontal cortex of vaccinated APP1PS1 mice. Our results suggest that the behavioral protection of long-term Ab vaccinations is task specific, with preservation of hippocampal-associated working memory tasks most likely to occur. In view of the early short-term memory deficits exhibited by AD patients, Ab vaccination of presymptomatic AD patients could be an effective therapeutic to protect against such cognitive impairments. 737 
INTRODUCTION B
RAIN DEPOSITION OF b-AMYLOID (Ab) appears to have a fundamental role in the pathogenesis of Alzheimer's disease (AD), as proposed by the amyloid cascade hypothesis (Hardy, 1997) . Studies supportive of this hypothesis show that: (1) inherited forms of AD involving mutations in amyloid precursor protein (APP) or presenilin 1 (PS1) genes result in overproduction of brain Ab (Scheuner et al., 1996) ; (2) Ab-containing neuritic plaques are present before clinical symptoms of AD become evident (Lippa et al., 1998) ; (3) Ab1-42 is toxic to neurons, especially in fibrillar form (Mattson et al., 1993; Lorenzo and Yankner, 1994) ; and (4) the extent of brain Ab deposition correlates with the degree of cognitive impairment in AD (Martin et al., 1987; Delaere et al., 1991) ; Naslund et al., 2000) . These findings suggest that therapeutics aimed at preventing or clearing brain Ab deposits could prevent or lessen the clinical manifestations of the disease.
An initial series of in vitro studies did, in fact, demonstrate that monoclonal antibodies raised against human Ab not only prevented aggregation of Ab but also resolubilized previously formed Ab aggregates (Solomon et al., 1996 (Solomon et al., , 1997 Frenkel et al., 1998) . Recently, in vivo work extended these findings with the demonstration that long-term vaccinations with human Ab prevented or markedly reduced brain Ab deposition in the PDAPP transgenic mouse model of AD (Schenk et al., 1999) . In addition to vaccinations with human Ab (active immunization), direct administration of Ab antibodies (passive immunization) has been shown to be effective in reducing Ab deposits (Bard et al., 2000) , primarily through increased clearance of deposited Ab by antibody-activated microglia. Importantly, neither of these later studies reported any behavioral consequences of long-term Ab vaccinations, leaving in question whether deleterious or beneficial effects would result.
Our own Ab vaccination studies have focused on transgenic mice carrying the human Swedish mutant APP (Tg2576), the human PS1 mutation (transgenic line 5.1), or both. Both APP (Tg2576) single-transgenic and APP1PS1 double-transgenic mice progressively develop Ab-containing neuritic plaques in the neocortex and hippocampus (Hsiao et al., 1996; Holcomb et al., 1998 Holcomb et al., , 1999 Takeuchi et al., 2000) . However, Ab deposition/plaque development is accelerated and enhanced in APP1PS1 mice, with all animals exhibiting some Ab deposits by 6 months and showing progressively increased deposition to a marked (20%-50%) Ab burden by 16 months Gordon et al., 2001) . Behaviorally, both APP and APP1PS1 mice exhibit normal cognition at 5 to 7 months of age in a wide range of tasks, including Y-maze, Morris water maze acquisition/retention, circular platform, visible platform, and radial arm water maze (RAWM) . By 15 to 17 months of age, however, both APP and APP1PS1 transgenic mice are impaired in Morris water maze acquisition, RAWM working memory, or both compared with nontransgenic mice unpublished observations) . Moreover, the extent of Ab deposition in 16-month APP1PS1 mice correlates strongly with their cognitive performance in the RAWM task , indicating that this difficult working memory task is sensitive to the extent of brain Ab deposition. In view of the age-related cognitive impairment in APP and APP1PS1 transgenic mice and their progressive Ab deposition, they would appear to be ideal models for testing the ability of Ab and Ab antibody vaccinations to prevent AD-related behavioral impairments.
Given the aforementioned ability of Ab vaccinations to reduce Ab deposition in the PDAPP transgenic AD model, determination of the behavioral consequences of Ab vaccinations in animal models of AD is critical for anticipating any deleterious or beneficial effects that clinical trials (already in progress) may show. In that context, we have recently reported that Ab vaccinations between 7.5 and 15.5 months of age partially protected APP and APP1PS1 mice from cognitive impairment in the RAWM, while providing a modest reduction in brain Ab deposition . In that initial report, data from several other sensorimotor/cognitive measures were not included, nor were correlations between Ab neuropathology and behavior. Therefore, the current study expands on our initial report by presenting: (1) effects of Ab vaccination on sensorimotor measures and an additional cognitive task (Ymaze spontaneous alternations); and (2) correlations between Ab neuropathology and behavior in Ab-and control-vaccinated APP1PS1 mice.
MATERIALS AND METHODS

Animals
Mice were obtained through breeding mutant Tg2576 APP mice with mutant PS1 line 5.1 transgenic mice, generating nontransgenic, APP, APP1PS1, and PS1 transgenic offspring with a mixed background (C57B6/SJL/SwissWebster/B6D2F1). On weaning, animals were genotyped by Southern blot analysis and initially group housed. Several weeks before onset of behavioral testing, animals were housed individually. A total of 30 mice began the present study at 5 to 7 months of age: 10 nontransgenic mice, 10 single-transgenic APP mice, and 10 double-transgenic APP1PS1 mice. All animals were permitted ad libitum access to rodent chow and water in a housing room immediately adjoining the behavioral testing room. Both rooms were maintained on a 12-hour light/dark cycle, with behavioral testing performed during the light phase.
General protocol
Between 5 and 7 months of age, animals were given a 6-week behavioral test battery. Thereafter, approximately equal numbers of animals in each of the three groups )nontransgenic, APP, and APP1PS1) began receiving inoculations with either human Ab1-42 or keyhole limpet hemocyanin (KLH) control vaccine. Following 4 months of Ab or KLH vaccination, animals (now aged 11.5 months) were retested in the RAWM. Vaccinations were continued through 15.5 months of age, at which time, animals received a second post-vaccination RAWM test. At 16 months of age, animals were evaluated for sensorimotor function (open field activity, balance beam performance, string suspension) and Y-maze spontaneous alternation behavior. A few days thereafter, all mice were killed and their brains processed for Ab immunohistochemistry or Congo red staining.
Vaccination procedures
Human Ab1-42 peptide (Bachem) was initially suspended in pyrogen-free type I water at a concentration of 2.2 mg/ml, then mixed with 103 PBS to yield 13 PBS. Incubation was carried out overnight at 37°C for use the next day. Control mice were inoculated with KLH. Antigenic suspensions of Ab and KLH were mixed 1:1 with Freund's complete adjuvant, and 100 mg of Ab or KLH was injected subcutaneously. Two weeks later, a boost of the same material (prepared freshly) was made in incomplete Freund's adjuvant, followed by monthly boosts for the next 3 months. Thereafter, monthly boosts of Ab or KLH in mineral oil were given. Vaccinations began at 7.5 months of age and ended at approximately 15.5 months of age. The first post-vaccination behavioral testing in the RAWM was started 5 days after the fifth vaccination, at 11.5 months of age. The second behavioral testing period began at 15.5 months, 1 month after the ninth vaccination. Only those animals surviving through the second behavioral testing period were included in the behavioral/histopathologic assessments. The size of the genotypic/treatment groups was six nontransgenic mice vaccinated with Ab or KLH, seven transgenic mice vaccinated with Ab (four APP1PS1, three APP), and seven transgenic mice vaccinated with KLH (five APP1PS1, two APP).
Behavioral assessment
Prevaccination behavioral assessment was done at 5 to 7 months of age through a 6-week behavioral battery , which included three sensorimotor tasks (open field, balance beam, and string agility) and five tasks having a cognitive component (Y-maze, Morris water maze, circular platform, visible platform, and RAWM). Postvaccination behavioral results involving RAWM testing at both 11.5 and 15.5 months have been previously reported . The current paper presents sensorimotor and Y-maze spontaneous alternation testing done at 16 months (8 months into vaccination) in the same animals. Correlation with Ab pathology involved all parametric behavioral tasks performed within several weeks of killing at 16 months (e.g., RAWM, open field behavior, balance beam, and Y-maze). We have previously described in detail our behavioral protocols for the tasks utilized in this study Arendash et al., 2001; Gordon et al., 2001 ) and provide additional descriptions below:
Radial arm water maze. The RAWM is carried out in a 100-cm circular pool with six swim alleys (30.5 cm long 3 19 cm wide) radiating from a common circular swim area 40 cm in diameter. An assortment of spatial cues is located on the testing room's walls and ceiling. A submerged escape platform 9 cm in diameter is placed near the end of a different arm for each day of testing, which forces mice to use working memory to perform this task (Knowlton et al., 1989) . A semirandom sequence of the remaining five arms is then selected as start arms for each of that day's trials. A different sequence of start arms is selected each day, which never includes that day's goal arm. Four consecutive acquisition trials (T1 through T4) give animals the opportunity to learn which arm contains the submerged platform for that day. A retention trial (T5), beginning from the one remaining start arm for that day, is administered 30 minutes after T4.
For any given trial, animals are placed in the designated start arm facing the common circular swim area. During the following 1-min maximum trial, each time an animal enters an incorrect arm (or fails to select an arm after 20 sec), it is gently pulled back to the start arm for that trial, and an error is charged. For each trial, the number of errors prior to escape onto the goal arm's submerged platform is recorded, as is the latency to escape. If the submerged platform is not located within a given 1-min trial, the mouse is guided to the submerged platform and assigned a latency score of 60 sec. Animals are allowed to remain on the platform for 30 sec before the next trial begins.
At the 15.5-month RAWM testing timepoint used for this study's correlation analysis, mice were tested for 11 days. Two animals in the Ab-vaccinated transgenic group were eliminated as nonperformers from RAWM data analysis because of a consistent lack of arm choices throughout the test period.
Open field activity. This single-trial test of activity and exploratory behavior involves an open black box (81 3 81 cm) with 28.5-cm walls. The box's floor is painted with lines (four horizontal and four vertical) to demarcate 16 squares of 20 3 20 cm each. For the single trial, each animal is admitted to the center of the box and allowed to explore for 5 min. The total number of line crossings over that period is recorded.
Balance beam. To evaluate balance and general motor function, a 1.1-cm wide dowel beam is attached to two support columns 43 cm above a padded surface. Attached at either end of the 51-cm long beam is a 14 3 10-cm platform. During the single day of testing, each animal is given three trials. For each trial, animals are placed at the center of the suspended beam and released. The time required for the animal to fall from the beam is recorded, and the scores from all three trials are averaged. If an animal remains on the beam for the duration of the 60-sec trial or escapes to one of the platforms, the maximum balance time of 60 sec is recorded.
String suspension. As a test of agility and grip capacity, animals are permitted to grasp a cotton string suspended 33 cm above a padded surface in the beam apparatus. Initially, animals are permitted to grasp the string only by their forepaws and are then released. During a single 60-sec trial, a 0 to 5 rating system is used to assess the performance of each animal: 0 5 unable to remain on string; 1 5 hangs by both forepaws; 2 5 attempts to climb onto string; 3 5 both forepaws and one or both hindpaws around string; 4 5 four paws and tail around string, with lateral movement; 5 5 escape.
Y-maze spontaneous alternations. To measure spontaneous alternation behavior and exploratory activity, a black Ymaze with arms 21 cm (l) 3 4 cm (w) with 40-cm walls is used. During a single 5-min trial, the sequence of arm choices is recorded. Spontaneous alternation, expressed as a percentage, refers to that proportion of arm choices differing from the previous two choices.
Histopathology studies
Within a few days of completion of behavioral testing at 16 months of age, mice were anesthetized with pentobarbital (100 mg/kg intraperitoneally) and perfused transcardially with 25 ml of isotonic saline. Brains were rapidly removed, and one hemisphere was immersion fixed in phosphate-buffered 4% paraformaldehyde for 24 h, then cryoprotected in a series of sucrose solutions. Using a sliding microtome, 25-mm frozen sections were collected in the horizontal plane. Sections were stored at 4°C in Dulbecco's PBS. Immunocytochemistry analysis for total Ab and Ab1-40 was performed on floating sections as previously described (Gordon et al., 1997) . Every twelfth section was stained for each marker.
The "total Ab" primary antiserum was raised in rabbits against Ab1-40 and recognizes both Ab1-40 and Ab1-42 in ELISA assays. Antiserum selective for Ab1-40 was purchased from Quality Controlled Biochemical (Hopkinton, MA). Staining selectivity was confirmed by preabsorption experiments, which blocked all punctate staining. Brain sections were incubated with the primary antibody overnight, as described previously . Nonspecific reaction products were negligible, as indicated by omitting the primary antibody or preincubating antisera with Ab. Also confirmatory of nonspecific antibody reactivity was the low background staining seen in nontransgenic mice. Congo red histologic staining was performed on slide-mounted sections that had been rehydrated for approximately 30 sec before staining. Hydrated sections were initially incubated in alkaline alcoholic saturated NaCl solution (2.5 mM NaOH in 80% reagent alcohol, freshly prepared) for 20 min, then incubated in 0.2% Congo red in alkaline alcoholic saturated NaCl solution for 30 minutes. After rinsing in three changes of 100% ethanol, sections were cleared through three changes of xylene, then coverslipped with Permount.
Image analysis
Congo red staining, as well as total Ab and Ab1-40 immunostaining, was quantified in both frontal cortex and hippocampus from 10 to 12 horizontal sections spaced 300 mm apart. The percent of the area occupied by stain was measured with a Videometric V150 image analysis system (Oncor) on a Nikon Microphot FX microscope by an experimenter unaware of the subject's genotype/treatment. The software uses hue, saturation, and intensity (HIS) to segment objects in the image field. Although both stain intensity and area were measured, only areas are reported here, as this is the conventional way of describing Ab deposits (amyloid burden). We have demonstrated (Gordon et al., 1997 ) that results are not qualitatively different between stain area, stain intensity, or their product (total immunoreactivity). Cortical and hippocampal values from a given mouse were averaged from all brain sections to represent the cortical and hippocampal values for that animal in statistical analysis.
Statistical analysis
Three genotype/treatment groups were evaluated statistically: nontransgenic controls, transgenic mice vaccinated with Ab, and transgenic mice receiving KLH control vaccinations. For open field activity, balance beam, and Y-maze percent alternation, ANOVA was used to determine if there was a difference among the three groups, with differences between groups resolved by post-hoc LSD analysis. Determination of group differences in the string agility task involved non-parametric analysis by Mann-Whitney U-tests. All group comparisons having P , 0.05 were deemed significant.
For APP1PS1 transgenic mice alone, correlation analysis between behavioral measures at 15.5 to 16 months and Ab neurohistology findings involved Pearson product-moment analysis. Single-day measures of open field activity, balance beam performance, and Y-maze alternation were utilized. For the multiple-day RAWM task, T4 and T5 values from the final 3 days of testing were used. The data from earlier days of testing largely reflect assimilation of animals to the procedural aspects of the task , while data from the final days are indicative of learning/working memory capacity.
RESULTS
Prevaccination behavioral testing
Between 5 and 7 months of age, all animals were tested in a 6-week behavioral battery to assess sensorimotor and cognitive skills prior to vaccination. Both the APP1PS1 and the APP transgenic groups performed as well as nontransgenic controls on all of the cognitive tasks, which included Y-maze alternation, Morris water maze, circular platform errors, visible plat-
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FIG. 1.
Balance beam performance and Y-maze percent spontaneous alternations at 16 months of age (after 8 months of vaccinations) in nontransgenic control (NT), transgenic KLH-vaccinated (Tg1 Con), and transgenic Ab-vaccinated (Tg1 Ab) mice. Both groups of transgenic mice, which had impaired balance beam performance prior to initiation of vaccinations, remained impaired. No effects of transgenicity or Ab vaccination were observed in Y-maze spontaneous alternations. *Significantly different from NT group at P , 0.005. form, and RAWM (data not shown). Among the sensorimotor tasks, however, both transgenic groups were impaired in balance beam performance prior to vaccinations (nontransgenic animals 42.7 6 6.2 sec, APP 11.1 6 4.8 sec*, APP1PS1 14.8 6 4.6 sec*; *P , 0.005 compared with nontransgenic mice).
Postvaccination behavioral testing
At 11.5 months of age, 4 months into vaccinations, RAWM testing revealed excellent learning/working memory for all animals, irrespective of genotype/treatment, as indicated in our earlier report . By 8 months into vaccinations, at 15.5 months of age, striking group differences in RAWM learning/working memory were apparent. The performance of Ab-vaccinated transgenic mice on the final days of testing was no different from that of nontransgenic controls for T4 and T5 and was significantly better than that of KLH-vaccinated transgenic mice for both T4 and T5 . The Ab-vaccinated transgenic mice did, however, require more trials than nontransgenic controls to achieve the same level of working memory performance. By contrast, KLHvaccinated transgenic mice made significantly more T4 and T5 errors than nontransgenic controls over all trials of testing and consistently performed at chance levels.
In sensorimotor testing performed at 16 months of age (after 8 months of vaccinations), the Ab-vaccinated and KLH-vaccinated transgenic mice were equally impaired in balance beam performance compared with nontransgenic controls (Fig. 1) . This impairment, present in both APP1PS1 and APP transgenic mice prior to the start of vaccinations (see above), thus was not ameliorated by Ab vaccinations. In open-field testing at 16 months, there were no group differences in activity/exploration behavior between nontransgenic, control-vaccinated transgenic, and Ab-vaccinated transgenic mice (line crossing: 154 6 15 vs. 239 6 70 vs. 174 6 85, respectively). Similarly, in the string agility task, there were no effects of transgenicity or Ab vaccination. In an additional cognitive-based task-Y-maze spontaneous alternation-there also was no effect of transgenicity or Ab vaccinations at 16 months (Fig. 1) .
Correlations between behavior and neuropathology
To determine whether the extent of Ab deposition in individual vaccinated APP1PS1 transgenic mice at 16 months was related to their behavioral performance, correlation analysis was performed. Although no correlations were found between Ab deposition and sensorimotor/Y-maze tasks, numerous highly significant correlations were evident between extent of compact Ab deposition (as indicated by Ab1-40 and Congo red staining) and RAWM performance. Thus, for all APP1PS1 transgenic animals combined (Ab-and KLH-vaccinated), strong correlations were evident between Ab1-40 immunostaining in hippocampus CA1 and RAWM errors for both T4 
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(r 5 0.86, P , 0.005; Fig. 2A ) and T5 (r 5 0.75, P , 0.05). Significant correlations were also present between frontal cortex Ab1-40 immunostaining and T4 errors (r 5 0.80, P , 0.02; Fig. 2B ), as well as between frontal cortex Congo red staining and T4 errors (r 5 0.79, P , 0.02; Fig. 2C ). Even when KLHvaccinated APP1PS1 mice were considered separately (N 5 5), significant correlations were observed between T4 errors and Ab1-40 immunostaining in both the hippocampal CA1 (r 5 0.925, P , 0.05; Fig. 2A ) and dentate gyrus (r 5 0.89, P , 0.05). Also, for KLH-vaccinated APP1PS1 mice alone, significant correlations were evident between T5 errors and Ab1-40 immunostaining in hippocampal CA1 (r 5 0.87, P , 0.05). Thus, the extent of compact Ab deposits in transgenic mice was associated with impaired learning/working memory in the RAWM task. By contrast, no correlations were found in either the frontal cortex or the hippocampus between total Ab immunostaining (which includes both compact and diffuse deposits) and RAWM impairment.
DISCUSSION
The results of this study clearly show that long-term vaccination with human Ab has no deleterious effects on sensorimotor or cognitive abilities in Alzheimer's transgenic mice. In fact, Ab vaccinations partially protect such mice from developing age-associated working memory impairment, as detailed in our initial report . Both Ab-and control-vaccinated transgenic mice performed as well as nontransgenic mice in RAWM testing at 11.5 months of age, 4 months into vaccinations. By 15.5 months of age (8 months into vaccinations), a second postvaccination RAWM test period revealed that control-vaccinated transgenic mice were markedly impaired, while Ab-vaccinated transgenic mice performed as well as nontransgenic mice by the end of daily testing. As the present study indicates, however, no beneficial behavioral effects of Ab vaccination were evident in several other tasks, either because task impairment was present in transgenic mice prior to onset of vaccination (e.g., balance beam) or because transgenic mice exhibited no task impairment (e.g., Y-maze, open field, string agility). Thus, the Ab vaccination effects were task specific, being protective against working memory deficits in the RAWM. Consequently, because vaccinations were begun at an age when APP1PS1 transgenic mice have some Abcontaining neuritic plaques (Holcomb et al., 1998) while showing normal cognitive abilities, our studies suggest that presymptomatic individuals destined to develop AD could be at least partially protected against cognitive impairment by Ab vaccination.
The main finding of the current report is that the behavioral benefit of Ab vaccination was primarily associated with the RAWM working memory task. The Y-maze spontaneous alternation testing at 16 months failed to reveal any impairment in transgenic mice, so there was no opportunity for Ab vaccinations to provide a beneficial effect in transgenic mice. The unimpaired Y-maze performance of transgenic mice is consistent with our prior results involving similarly aged transgenic mice (King et al., 1999; Arendash et al., 2001) . Our collective results support the view that the Y-maze task can be relatively insensitive to cognitive impairment in AD transgenic mice and may have some age specificity. Along that line, we have found an overall Y-maze alternation impairment in Tg2576 transgenic mice when all four ages between 3 and 19 months (N 5 801 mice) were included in the analysis, as well as at the outer 3-and 19-month time points separately (King and Arendash, manuscript submitted) . Similarly, Holcomb et al. (1998 Holcomb et al. ( , 1999 found Y-maze deficits in APP1PS1 mice as early as 3 months of age.
In the present study, no effects of transgenicity or Ab vaccination were evident in open-field activity or string agility. However, balance beam impairment, present in transgenic mice before the start of Ab vaccinations, was not reversed or lessened by Ab vaccination. Thus, established sensorimotor impairments may not be readily decreased by Ab vaccinations. Indeed, any prior behavioral impairment-either sensorimotor or cognitive-may be difficult to treat through Ab vaccinations, particularly as Ab deposition becomes more extensive in old age, and the resultant damage to the neuropil presumably becomes less reversible.
Because Ab-depositing transgenic mice exhibit focal neuroinflammation, as evidenced by high numbers of plaque-associated microglia/astrocytes (Frautschy et al., 1998; Benzing et al., 1999; Mehlhorn et al., 2000) , we anticipated the possibility that Ab vaccinations might actually exacerbate ongoing neuroinflammatory processes and consequently result in deleterious behavioral effects. However, no deleterious effects of Ab vaccination were seen in any of the sensorimotor and cognitive tasks administered just prior to killing at 16 months (8 months into vaccination). Indeed, protective effects on working memory were observed in RAWM testing performed within several weeks of killing.
As indicated in our initial report , the 8-month vaccination protocol used in this study resulted in very high Ab antibody titers at 16 months in both transgenic and nontransgenic mice vaccinated with Ab, but no anti-Ab activity in unvaccinated or KLH-vaccinated control mice. Moreover, this protocol produced modest (< 25%) reductions in cortical/hippocampal Ab deposition in 16-month-old transgenic mice, as indicated by Congo red and Ab immunostaining. It will be important to determine if initiating vaccinations at an earlier age or in combination with other anti-Ab therapeutics could result in a more extensive reduction of Ab deposits and complete protection against working memory deficits. Equally important is the need to determine if cognitive benefits provided by Ab vaccinations extend to reference (long-term) learning/memory function. Because we find both APP and APP1PS1 mice to be learning impaired in Morris water maze reference memory at 15 to 17 months but not at 5 to 7 months , the present vaccination protocol could be utilized in such animals to elucidate any learning/reference memory benefits of Ab vaccinations. Along this line, Janus et al. (2000) reported that Ab vaccinations between 1.5 and 5 months of age in the TgCRND8 transgenic AD model partially restores Morris maze reference learning.
There are several mechanisms that could singularly, or in combination, be responsible for the beneficial cognitive effects of Ab vaccination in the RAWM and associated reduction in Ab deposition. Initial in vitro studies showed that monoclonal antibodies against human Ab can prevent Ab aggregation and induce disaggregation of Ab fibrils (Solomon et al., 1996; 1997) , apparently through binding to Ab's N-terminal EFRH epitope-a regulatory site involved with both solubilization and disaggregation (Frenkel et al., 1998) . Thus, a direct effect of Ab antibodies on Ab aggregation, possibly through binding to highly neurotoxic intermediate Ab assemblies called protofibrils Hartley et al., 1999) , is one possible mechanism of action. A second and perhaps interrelated mechanism involves Ab antibody stimulation of plaque-associated microglia to enhance clearance of deposited Ab through phagocytosis/degradation. Supportive of this mechanism, plaque-associated microglia exposed to Ab antibodies (but not control antibodies) have numerous vesicles laden with engulfed Ab (Schenk et al., 1999; Bard et al., 2000) . This microglial phagocytosis of deposited Ab involves Ab antibody stimulation of Fc receptors and is followed within several days by degradation of all engulfed Ab (Bard et al., 2000) . Consistent with microglial phagocytosis/degradation of deposited Ab following long-term Ab vaccination is the decrease in total brain Ab (via ELISA) that also is observed (Schenk et al., 1999) .
We have previously reported that the RAWM task is very sensitive to the extent of brain Ab deposition in APP1PS1 mice , which develop large Ab burdens by 15 to 17 months of age. Results from the present study further underscore and extend this pathology/RAWM association by showing strong correlations between compact Ab deposits (as indicated by Ab1-40 or Congo red staining) and RAWM working memory impairment for all APP1PS1 mice. The fact that no correlations were found between total Ab (both compact and diffuse Ab deposits) and RAWM performance indicates that compact Ab deposits are more involved with working memory impairment than loosely deposited Ab.
Because APP1PS1 mice given Ab vaccinations had fewer RAWM errors and reduced Ab deposition compared with KLHvaccinated transgenic animals, they were clustered near the bottom of all correlation graphs. However, even when Ab-vaccinated APP1PS1 mice were omitted from the analysis and only the five KLH-vaccinated APP1PS1 mice were included, correlations between Ab1-40 immunostaining and RAWM performance continued to be significant. Clearly, the modest number of animals needed to reveal these RAWM correlations, as well as the lack of any correlations between Ab pathology and the other behavioral tasks investigated, indicates exquisite sensitivity of the RAWM task to Ab deposition. Moreover, the fact that significant correlations between hippocampal (CA1 and dentate gyrus) Ab and RAWM impairment could be attained only with KLH-treated animals underscores the hippocampal dependence of this task and its close inverse relation to hippocampal compact Ab deposition.
Our initial study provided solid support for the amyloid cascade hypothesis of AD (Hardy, 1997) by demonstrating that a therapeutic agent that reduces Ab deposition during aging (i.e., Ab vaccination) also protects against the development of age-associated impairment in working memory. It should be noted, however, that both the Ab reduction and the behavioral benefit induced by Ab vaccination were incomplete, suggesting: (1) less than optimal influx of Ab antibodies into the central nervous system; (2) an upper limit to the amount of Ab that can be removed; or (3) involvement of some other proteolytic APP fragment(s) in Ab deposition/behavioral impairment. What does seem clear is that the ability of Ab vaccinations to reduce brain Ab deposition does not rely on cellular immunity (T-lymphocyte activation), as mice inoculated directly with Ab antibodies (passive immunization) exhibit reductions in brain Ab deposition similar to those seen after active Ab vaccination (Bard et al., 2000) . Whether such passive immunization provides the same behavioral benefits as active Ab immunization will be important to evaluate. Other therapeutics that reduce Ab deposition in transgenic micemost notably nonsteroidal anti-inflammatory drugs (Lim et al., 2000) , copper/zinc chelators (Bush et al., 2000) , and blueberry extract (Bielinski et al., 2000) -may also provide behavioral benefits and are being investigated by our laboratories.
In conclusion, the absence of deleterious behavioral effects and the protective cognitive actions of Ab vaccinations in AD transgenic mice suggest that this and other Ab-reducing approaches could have marked beneficial effects against AD. Especially if a diagnostic measure becomes available for AD, our present study suggests that Ab vaccinations in individuals destined to develop the disease may partially protect them against AD symptomology.
